SeaStar Medical Holding Corporation (ICU)vsRegeneron Pharmaceuticals Inc (REGN)
ICU
SeaStar Medical Holding Corporation
$3.28
-7.08%
HEALTHCARE · Cap: $11.75M
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1038869% more annual revenue ($14.92B vs $1.44M). REGN leads profitability with a 29.6% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 64/100 (C+).
ICU
Avoid30
out of 100
Grade: F
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ICU.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 68.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -162.7% — below average capital efficiency
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ICU
The strongest argument for ICU centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 68.9% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ICU
The primary concerns for ICU are EPS Growth, Market Cap, Profit Margin.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ICU profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.30 — expect wider price swings.
ICU is growing revenue faster at 68.9% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 30/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
SeaStar Medical Holding Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
SeaStar Medical Holding Corporation (ICU) is an innovative biotechnology company committed to improving treatment options for chronic kidney disease through its proprietary technologies aimed at enhancing renal function and minimizing the need for invasive procedures. Operating in a growing market with significant unmet medical needs, SeaStar is dedicated to clinical innovation and excellence. Supported by a strong research and development pipeline and strategic collaborations, the company is well-positioned to make impactful advancements in renal health and expedite the commercialization of its groundbreaking therapies.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?